Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis

Leukemia volume 28, pages 2304–2310 (2014)Cite this article

Subjects

Abstract

Despite improvements in therapy amyloid light-chain (AL) amyloidosis, there are few studies comparing different regimens. Here we present a matched comparison with 69 patients in each cohort examining upfront therapy with cyclophosphamide, bortezomib and dexamethasone (CVD) vs cyclophosphamide, thalidomide and dexamethasone (CTD). On an intention-to-treat basis, the overall response rates were 71.0% vs 79.7% in the CVD and CTD arms, respectively, (P=0.32). A higher complete response (CR) rate was observed in the CVD arm (40.5%) vs CTD (24.6%), P=0.046. One-year overall survival (OS) was 65.2% and 66.7% for CVD and CTD, respectively (P=0.87). The median progression-free survival (PFS) was 28.0 and 14.0 m for CVD and CTD, respectively (P=0.039). In a landmark analysis assessing outcomes performed at 6 months, the CR rate with CVD was 59.6% vs 34.0% for CTD (P=0.03). The 1-year OS was 96% with CVD and 92% with CTD (P=0.40). The median PFS with CVD was not reached and was 19.2 m with CTD, P=0.028). In summary, both regimens are unable to overcome the high rate of early deaths in AL amyloidosis. However, CVD correlates with improved depth of response and superior PFS supporting its use in the frontline setting. Further optimisation and better supportive-care strategies are required to increase the proportion of patients fully benefiting from therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Perfetti V, Vignarelli MC, Casarini S, Ascari E, Merlini G . Biological features of the clone involved in primary amyloidosis (AL). Leukemia 2001; 15: 195–202.

    Article  CAS  Google Scholar 

  2. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121: 3420–3427.

    Article  CAS  Google Scholar 

  3. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989–995.

    Article  CAS  Google Scholar 

  4. Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881–1887.

    Article  CAS  Google Scholar 

  5. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202–1207.

    Article  CAS  Google Scholar 

  6. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083–1093.

    Article  CAS  Google Scholar 

  7. Palladini G, Perfetti P, Obici L, Caccialanza R, Semino A, Adami F et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936–2938.

    Article  CAS  Google Scholar 

  8. Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007; 110: 787–788.

    Article  CAS  Google Scholar 

  9. Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC . Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica 2013; 98: 789–792.

    Article  CAS  Google Scholar 

  10. Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2013; 98: 433–436.

    Article  CAS  Google Scholar 

  11. Tovar N, Cibeira MT, Rosiñol L, Solé M, de Larrea CF, Escoda L et al. Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease. Eur J Haematol 2012; 89: 340–344.

    Article  CAS  Google Scholar 

  12. Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol 2012; 91: 89–92.

    Article  CAS  Google Scholar 

  13. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013; 27: 823–828.

    Article  CAS  Google Scholar 

  14. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012; 119: 4860–4867.

    Article  CAS  Google Scholar 

  15. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012; 119: 5384–5390.

    Article  CAS  Google Scholar 

  16. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 2012; 119: 5397–5404.

    Article  CAS  Google Scholar 

  17. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011; 118: 865–873.

    Article  CAS  Google Scholar 

  18. Venner CP, Lane T, Foard D, Rannigan L, Gibbs SDJ, Pinney JH et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119: 4387–4390.

    Article  CAS  Google Scholar 

  19. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119: 4391–4394.

    Article  CAS  Google Scholar 

  20. Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD . Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457–464.

    Article  CAS  Google Scholar 

  21. Gillmore J, Cocks K, Gibbs S, Sattianayagam PT, Lane T, Lachmann H et al. Cyclophosphamide, thalidomide and dexamethasone (ctd) versus melphalan plus dexamethasone (MD) for newly-diagnosed systemic al amyloidosis—results from the UK amyloidosis treatment trial. Blood (ASH Annu Meet Abstr) 2009; 114: Abstract 745.

  22. Gibbs S, Gillmore JD, Sattianayagam PT, Lachmann HJ, Lane T, Goodman H et al. CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched case-control study. Amyloid 2010; 17 (Suppl 1): 83.

    Google Scholar 

  23. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949–2951.

    Article  CAS  Google Scholar 

  24. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009; 113: 3040–3049.

    Article  CAS  Google Scholar 

  25. Oliva L, Palladini G, Cerruti F, Pengo N, Cascio P, Merlini G et al. Assessing proteostasis and proteasome stress in light chain amyloidosis. Blood 2010; 116: 3992.

    Google Scholar 

  26. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031–1037.

    Article  CAS  Google Scholar 

  27. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD . Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295–298.

    Article  CAS  Google Scholar 

  28. Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC . Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica 2011; 96: 1890–1892.

    Article  CAS  Google Scholar 

  29. Gertz MA, Comenzo R, Falk RH, Fermand J-P, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319–328.

    Article  Google Scholar 

  30. Gertz MA, Merlini G . Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010; 17: 2.

    Article  Google Scholar 

  31. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia 2012; 26: 2317–2325.

    Article  CAS  Google Scholar 

  32. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541–4549.

    Article  CAS  Google Scholar 

  33. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV . Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013; 27: 941–946.

    Article  CAS  Google Scholar 

  34. Wechalekar AD, Gillmore JD, Foard D, Rannigan L, Lane T, Pinney JH et al. Evaluation of an early switch to second line chemotherapy in AL amyloidosis among patients who fail to achieve a very good partial response to frontline treatment. XIII Symposia of the International Society of Amyloidosis, 2012, Groeningen, Netheralands, (OP 60).

    Google Scholar 

  35. Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D et al. Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol 2011; 29: 674–681.

    Article  Google Scholar 

  36. Lane T, Rannigan L, Foard D, Wechalekar A, Gibbs S . ALchemy-A large prospective ‘Real World’ Study of Chemotherapy in AL Amyloidosis. Blood 2011; 118: Abstract 992.

  37. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118: 4346–4352.

    Article  CAS  Google Scholar 

  38. Cordes S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 2012; 118: 6105–6109.

    Article  CAS  Google Scholar 

  39. Warsame R, Bang S-M, Kumar SK, Lacy MQ, Buadi FK, Buadi F et al. Outcomes and treatments of relapsed al amyloidosis following stem cell transplant. Blood 2012; 120: 1858.

    Google Scholar 

  40. Pinney JH, Lachmann HJ, Sattianayagam PT, Gibbs SDJ, Wechalekar AD, Venner CP et al. Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. Am J Transplant 2013; 13: 433–441.

    Article  CAS  Google Scholar 

  41. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440–2445.

    Article  CAS  Google Scholar 

  42. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem-cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013; 27: 823–828.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, UK

    C P Venner, J D Gillmore, S Sachchithanantham, S Mahmood, T Lane, D Foard, L Rannigan, S D J Gibbs, J H Pinney, C J Whelan, H J Lachmann, P N Hawkins & A D Wechalekar

  2. Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada

    C P Venner

  3. Department of Clinical Haematology, Manchester Royal Infirmary, Central Manchester University Hospitals, Manchester, UK

    S D J Gibbs

Authors
  1. C P Venner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J D Gillmore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Sachchithanantham
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Mahmood
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Foard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Rannigan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S D J Gibbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J H Pinney
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C J Whelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H J Lachmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P N Hawkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A D Wechalekar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A D Wechalekar.

Ethics declarations

Competing interests

CPV has received honoraria from Celgene and Johnson & Johnson. ADW has received honoraria from Jansen Cilag. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Venner, C., Gillmore, J., Sachchithanantham, S. et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia 28, 2304–2310 (2014). https://doi.org/10.1038/leu.2014.218

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.218

This article is cited by

Search

Advanced search

Quick links